Fundraising Fox
/Companies
Sign in

Eccogene

Cambridge, US · Founded 2018 · 32 employees on LinkedIn · 9 known investors

Find your way into Eccogene

Sign up to see every warm intro you have to Eccogene

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Eccogene team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease. Its pipeline includes GLP-1 receptor agonist, THR-β, and SSAO programs, with its lead asset ECC5004 licensed to AstraZeneca.

BiotechHealthtech

Founders & leadership

Eccogene was founded in 2018 by Jingye Zhou, Jingye Zhou, Ph.D., and Jianfeng Xu, Ph.D..

JZJingye Zhou
Jingye ZhouCo-founder and CEOJingye Zhou is the founder of Eccogene, a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions. He has spent decades in small molecule drug discovery with expertise in metabolic diseases, immune metabolism, and cancer metabolism.
JZ
Jingye Zhou, Ph.D.Co-founder & CEO
JX
Jianfeng Xu, Ph.D.Co-founder & CSO

Investors · 9

New Alliance CapitalreportedShanghai

How we know: funding news · deloscapital.com · Not right? Tell us

Also in the syndicate · 7

Elikon VentureHuajin CapitalOriza Seed CapitalQingsong CapitalRockbleu CapitalYuFu InvestmentZhangjiang Healthcare Venture Capitallead

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries BJun 2023

    New Alliance Capital (lead), Zhangjiang Healthcare Venture Capital (lead), Delos Capital, Elikon Venture, Huajin Capital, Oriza Seed Capital, Qingsong Capital, Rockbleu Capital, YuFu Investment

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetesglobenewswire.com · Oct 2024

Frequently asked questions

What does Eccogene do?
Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease. Its pipeline includes GLP-1 receptor agonist, THR-β, and SSAO programs, with its lead asset ECC5004 licensed to AstraZeneca.
Who founded Eccogene?
Eccogene was founded by Jingye Zhou, Jingye Zhou, Ph.D., Jianfeng Xu, Ph.D. in 2018.
Who are Eccogene's investors?
Eccogene's investors include Delos Capital, New Alliance Capital.
Where is Eccogene headquartered?
Eccogene is headquartered in Cambridge, US.